Feb. 3 at 11:02 PM
$GNPX has a habit of moving exactly when people get bored. We’re in that quiet window right now, but if you look at the calendar, the board is basically set for a massive few months. 📊
In case you missed the recent updates, here is what we are actually waiting on:
First is the Diabetes play (GPX-002). After those solid results in Jan, they officially requested the FDA meeting. We are just waiting on feedback now. If that path to human trials gets cleared, the story changes overnight. 💉
Then you have the cancer trials. Acclaim-1 is coming up on a major de-risking event with enrollment for the first 19 patients wrapping up by end of Q1. Acclaim-3 is doing the same with its first 25 patients.
Data is everything in this sector and having two high-impact readouts lined up like this is rare for a microcap.
The chart is coiled and holding support here. I’d much rather be early & patient than chasing a massive green candle once these updates hit. 🔋🚀
